S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
NASDAQ:SRPT

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

$132.29
-3.85 (-2.83%)
(As of 02/21/2024 ET)
Today's Range
$130.50
$136.25
50-Day Range
$90.29
$136.14
52-Week Range
$55.25
$159.89
Volume
805,963 shs
Average Volume
1.25 million shs
Market Capitalization
$12.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$157.55

Sarepta Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
19.1% Upside
$157.55 Price Target
Short Interest
Healthy
5.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.63mentions of Sarepta Therapeutics in the last 14 days
Based on 42 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.57) to $2.43 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.33 out of 5 stars

Medical Sector

134th out of 932 stocks

Pharmaceutical Preparations Industry

54th out of 431 stocks


SRPT stock logo

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Stock Price History

SRPT Stock News Headlines

Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data (SRPT)
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MarketBeat Week in Review: 1/22 - 1/26 (SRPT)
Markets continued to push to new all-time highs, setting the stage for big tech earnings, which will happen next week; here are the top stories from this week.
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
SRPT Mar 2024 30.000 call
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up on Analyst Upgrade
SRPT Feb 2024 130.000 call
Sarepta stock jumps on FDA nod for ELEVIDYS gene therapy
Sarepta Says FDA Accepted Efficacy Supplement To BLA For Elevidys
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/22/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,162
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$157.55
High Stock Price Target
$224.00
Low Stock Price Target
$109.00
Potential Upside/Downside
+19.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
18 Analysts

Profitability

Net Income
$-703,490,000.00
Pretax Margin
-59.89%

Debt

Sales & Book Value

Annual Sales
$933.01 million
Book Value
$4.39 per share

Miscellaneous

Free Float
86,625,000
Market Cap
$12.38 billion
Optionable
Optionable
Beta
0.93

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Douglas S. Ingram Esq.Mr. Douglas S. Ingram Esq. (Age 61)
    President, CEO & Director
    Comp: $1.62M
  • Mr. Ian Michael Estepan (Age 48)
    Executive VP & CFO
    Comp: $917.53k
  • Dr. Louise R. Rodino-Klapac Ph.D. (Age 46)
    Executive VP, Chief Scientific Officer and Head of Research & Development
    Comp: $1.04M
  • Mr. Ryan E. Brown J.D. (Age 46)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $823.36k
  • Mr. Bilal Arif (Age 52)
    Executive VP & Chief Technical Operations Officer
  • Ms. Francesca T. Nolan
    Executive Director of Investor Relations and Corporate Communications
  • Ms. Alison Nasisi
    Executive VP & Chief People Officer
  • Dr. Diane L. Berry Ph.D.
    Executive VP and Chief of Global Policy & Advocacy Officer
  • Mr. Dallan Murray
    Executive VP & Chief Customer Officer
  • Mr. Will Tilton
    Senior VP, Head of Strategy & Chief of Staff














SRPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price target for 2024?

18 Wall Street analysts have issued 12-month target prices for Sarepta Therapeutics' shares. Their SRPT share price targets range from $109.00 to $224.00. On average, they predict the company's share price to reach $157.55 in the next year. This suggests a possible upside of 19.1% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2024?

Sarepta Therapeutics' stock was trading at $96.43 at the start of the year. Since then, SRPT stock has increased by 37.2% and is now trading at $132.29.
View the best growth stocks for 2024 here
.

Are investors shorting Sarepta Therapeutics?

Sarepta Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 5,170,000 shares, a drop of 9.0% from the January 15th total of 5,680,000 shares. Based on an average trading volume of 1,250,000 shares, the short-interest ratio is presently 4.1 days.
View Sarepta Therapeutics' Short Interest
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of ($1.63) by $2.00. The biotechnology company had revenue of $331.80 million for the quarter, compared to analysts' expectations of $285.33 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 46.23% and a negative net margin of 62.52%. The business's revenue was up 44.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.94) EPS.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.42%), Capital International Investors (5.07%), Avoro Capital Advisors LLC (4.64%), Norges Bank (0.89%), Price T Rowe Associates Inc. MD (0.79%) and Price T Rowe Associates Inc. MD (0.79%). Insiders that own company stock include Douglas S Ingram, Hans Lennart Rudolf Wigzell, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
This page (NASDAQ:SRPT) was last updated on 2/22/2024 by MarketBeat.com Staff